Advancing the development of a genetically-informed behavioral intervention to promote tobacco treatment and cessation

Alex Ramsey, Li-Shiun Chen, Laura Bierut
Department of Psychiatry, Washington University School of Medicine

Genetic variation in nicotinic receptor subunits explains differences in smoking behaviors and risk of smoking-related diseases. Personalized genetic risk results specific to smoking may motivate engagement in tobacco treatment, yet this is largely untested. We developed a personalized genetic risk communication tool (called ‘RiskProfile’) and examined acceptability and potential behavior change among current smokers.

Current smokers (n=108) were enrolled in a single arm trial with three visits. At Visit 1, participants completed a baseline assessment and genetic testing via 23andMe. Participants’ raw genetic data (CHRNA5 variants) and smoking heaviness were used to create a tailored RiskProfile tool that communicated personalized risks of smoking-related diseases and evidence-based recommendations to promote cessation. Participants received their personalized RiskProfile at Visit 2, approximately 6 weeks later. Participants completed follow-up assessments at Visit 3, 30 days after receiving RiskProfile.

Of enrolled participants, 83% were retained across study visits. Acceptability of RiskProfile was high (\(M=4.4; SD=0.6\) on scale of 1 to 5), and 89% of participants demonstrated accurate recall of key RiskProfile messages. Following intervention receipt, 37% of current smokers reported increased desire to use smoking cessation pharmacotherapy, and 21% reported initiating smoking cessation pharmacotherapy. Additionally, cigarettes smoked per day decreased between receipt of RiskProfile and 30-day follow-up [11.3 vs. 9.8, difference=1.5, 95% CI (0.6—2.4), \(p=.001\)].

A personalized genetic risk communication tool was found to be highly acceptable and associated with increased treatment use and reduced smoking. This study reflects an innovative application of genomic data to personalize and promote use of evidence-based tobacco treatment.